Combination Therapy for Leishmaniases

[1]  Sassan Noazin,et al.  Immunological stimulation for the treatment of leishmaniasis: a modality worthy of serious consideration. , 2015, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[2]  S. Sundar,et al.  Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial , 2011, The Lancet.

[3]  S. Sundar,et al.  Cost-Effectiveness Analysis of Combination Therapies for Visceral Leishmaniasis in the Indian Subcontinent , 2010, PLoS neglected tropical diseases.

[4]  Shyam Sundar,et al.  Single-dose liposomal amphotericin B for visceral leishmaniasis in India. , 2010, The New England journal of medicine.

[5]  Manica Balasegaram,et al.  Combination therapy for visceral leishmaniasis. , 2010, The Lancet. Infectious diseases.

[6]  P. Leprohon,et al.  Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  M. Rai,et al.  New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  S. Croft,et al.  Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo. , 2007, International journal of antimicrobial agents.

[9]  S. Sundar,et al.  Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. , 2007, The Journal of infectious diseases.

[10]  Shyam Sundar,et al.  Injectable paromomycin for Visceral leishmaniasis in India. , 2007, The New England journal of medicine.

[11]  R. Coler,et al.  Immunotherapy for drug-refractory mucosal leishmaniasis. , 2006, The Journal of infectious diseases.

[12]  R. Davidson,et al.  A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  O. Zerpa,et al.  Immunotherapy of american cutaneous leishmaniasis in Venezuela during the period 1990-99. , 2003, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[14]  Shyam Sundar,et al.  Oral miltefosine for Indian visceral leishmaniasis. , 2002, The New England journal of medicine.

[15]  F. Modabber,et al.  Immunochemotherapy for cutaneous leishmaniasis: a controlled trial using killed Leishmania (Leishmania) amazonensis vaccine plus antimonial , 2002, International journal of dermatology.

[16]  M. Robert-Gero,et al.  Development and characterization of paromomycin-resistant Leishmania donovani promastigotes. , 1998, Parasite.

[17]  P. Olliaro,et al.  Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India. , 1998, BMJ.

[18]  C. P. Thakur,et al.  Aminosidine plus sodium stibogluconate for the treatment of Indian kala-azar: a randomized dose-finding clinical trial. , 1995, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[19]  Sassan Noazin,et al.  Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment. , 2008, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[20]  S. Croft,et al.  Chemotherapy in the treatment and control of leishmaniasis. , 2006, Advances in parasitology.

[21]  J. Berman,et al.  Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. , 1998, Bulletin of the World Health Organization.